These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20048699)

  • 1. Specificities of broadly neutralizing anti-HIV-1 sera.
    Binley J
    Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges for structure-based HIV vaccine design.
    Schief WR; Ban YE; Stamatatos L
    Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
    Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
    Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
    Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
    Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
    Euler Z; van Gils MJ; Bunnik EM; Phung P; Schweighardt B; Wrin T; Schuitemaker H
    J Infect Dis; 2010 Apr; 201(7):1045-53. PubMed ID: 20170371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to conserved epitopes of the HIV-1 envelope in sera from long-term non-progressors: prevalence and association with neutralizing activity.
    Braibant M; Brunet S; Costagliola D; Rouzioux C; Agut H; Katinger H; Autran B; Barin F
    AIDS; 2006 Oct; 20(15):1923-30. PubMed ID: 16988513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
    Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
    J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New virologic reagents for neutralizing antibody assays.
    Ochsenbauer C; Kappes JC
    Curr Opin HIV AIDS; 2009 Sep; 4(5):418-25. PubMed ID: 20048706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.
    Humbert M; Antoni S; Brill B; Landersz M; Rodes B; Soriano V; Wintergerst U; Knechten H; Staszewski S; von Laer D; Dittmar MT; Dietrich U
    Eur J Immunol; 2007 Feb; 37(2):501-15. PubMed ID: 17236253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization and infectivity characteristics of envelope glycoproteins from human immunodeficiency virus type 1 infected donors whose sera exhibit broadly cross-reactive neutralizing activity.
    Cham F; Zhang PF; Heyndrickx L; Bouma P; Zhong P; Katinger H; Robinson J; van der Groen G; Quinnan GV
    Virology; 2006 Mar; 347(1):36-51. PubMed ID: 16378633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catch Me If You Can--The Race Between HIV and Neutralizing Antibodies.
    Geiß Y; Dietrich U
    AIDS Rev; 2015; 17(2):107-13. PubMed ID: 26035168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
    Jülg B; Goebel FD
    Infection; 2005 Oct; 33(5-6):405-7. PubMed ID: 16258878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of neutralizing antibodies in HIV infection.
    Humbert M; Dietrich U
    AIDS Rev; 2006; 8(2):51-9. PubMed ID: 16848273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
    Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
    Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.
    Pancera M; Wyatt R
    Virology; 2005 Feb; 332(1):145-56. PubMed ID: 15661147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies that cross-neutralize the tier-2 pseudoviruses are produced in antiretroviral-naïve HIV-1-infected children from northern India.
    Prakash SS; Andrabi R; Kumar R; Lodha R; Kabra SK; Vajpayee M; Luthra K
    Arch Virol; 2012 Sep; 157(9):1797-801. PubMed ID: 22674340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.